Alnylam Pharmaceuticals Reports 96% Revenue Growth to $1.17 Billion in Latest Quarter

Alnylam Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly results, with total revenues reaching $1.17 billion for the three months ended March 31, 2026, a 96% increase from $594.2 million in the same period last year. This surge was primarily driven by a substantial rise in net product revenues, which soared by 121% to $1.04 billion, largely attributed to the strong performance of AMVUTTRA, which generated $889.9 million in sales, a 187% increase compared to the previous year. The company also reported a net income of $206 million, a notable turnaround from a loss of $18.3 million in the prior year, marking its first profitable quarter.

In terms of operational changes, Alnylam's product portfolio has expanded, with six marketed products, including AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO. The company has also made strategic advancements, including the initiation of Phase 3 clinical trials for its investigational RNAi therapeutics, nucresiran and zilebesiran, as part of its "Alnylam 2030" strategy aimed at expanding its clinical pipeline and market presence. The company’s collaboration with Roche for zilebesiran has been particularly noteworthy, with Alnylam receiving significant milestone payments and sharing in the development costs.

Alnylam's operational metrics reflect a growing customer base and increased engagement, with AMVUTTRA's adoption significantly contributing to revenue growth. The company reported a total of 910,412 units sold for AMVUTTRA and ONPATTRO combined, although ONPATTRO sales declined by 59% to $20.5 million, indicating a shift in market dynamics. The company’s workforce has also expanded, supporting its increased research and development activities, which totaled $364.9 million for the quarter, up 38% from the previous year.

Looking ahead, Alnylam anticipates continued growth driven by its expanding product offerings and ongoing clinical trials. The company expects to maintain its momentum in revenue generation, particularly from AMVUTTRA, while also investing in research and development to support its pipeline of RNAi therapeutics. However, the company acknowledges the inherent risks in drug development and market competition, which could impact future performance. Alnylam's management remains optimistic about achieving its long-term goals, including a compound annual growth rate of over 25% in total revenue and a 30% operating margin by the end of 2030.